Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GNI Group ( (JP:2160) ) has provided an update.
GNI Group Ltd. has announced corrections to previously disclosed non-consolidated financial results for the fiscal year ended December 31, 2025, after determining that tax expenses related to Controlled Foreign Corporation taxation for its wholly owned subsidiary GNI Hong Kong Limited had been overstated. Following discussions with its accounting auditor, the company also revised the valuation of shares in a subsidiary and the recoverability of related loans, resulting in the recognition of a loss on valuation of subsidiary shares and an allowance for doubtful accounts in its non-consolidated financial statements.
As a result of these adjustments under Japanese GAAP, GNI’s non-consolidated figures for ordinary income and net income for 2025 were revised downward, deepening the previously reported loss at the parent-company level. However, the company emphasized that these valuation losses and allowances are eliminated on consolidation, meaning there is no impact on its consolidated IFRS-based financial results, which should help reassure investors that the group’s overall financial position and performance remain unchanged despite the non-consolidated revisions.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen3192.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-listed biopharmaceutical company on the TSE Growth market, focused on developing and commercializing innovative therapies through its network of subsidiaries, including GNI Hong Kong Limited. The group operates under both IFRS for consolidated reporting and Japanese GAAP for non-consolidated accounts, reflecting a cross-border structure that requires complex tax and accounting treatments.
Average Trading Volume: 1,412,564
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen169.3B
For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.